Skip to main content

Effectiveness of a carbohydrate restricted diet to treat non-alcoholic fatty liver disease in adolescents with obesity: Trial design and methodology.

Citation
Dowla, S., et al. “Effectiveness Of A Carbohydrate Restricted Diet To Treat Non-Alcoholic Fatty Liver Disease In Adolescents With Obesity: Trial Design And Methodology.”. Contemporary Clinical Trials, pp. 95-101.
Center University of Alabama at Birmingham
Author Shima Dowla, May Pendergrass, Mark Bolding, Barbara Gower, Kevin Fontaine, Ambika Ashraf, Taraneh Soleymani, Shannon Morrison, Amy Goss
Keywords adolescent, Carbohydrate restriction, Childhood obesity, Diet intervention, non-alcoholic fatty liver disease
Abstract

BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is the most common liver disorder among children in the developed world and can progress to cirrhosis, hepatocellular carcinoma, and liver failure. No evidence-based dietary guidelines exist on the most effective diet prescription to treat NAFLD.

OBJECTIVE: To compare the effect of a carbohydrate (CHO)-restricted diet vs fat-restricted diet, the current standard of care, on changes in hepatic fat infiltration, body composition, and metabolic health over an 8-week period among overweight and obese children diagnosed with NAFLD.

METHODS: In this two-arm, parallel design randomized controlled trial (RCT), 40 participants aged 9 to 18 years were randomized to a CHO restricted diet (<25:>50:25% daily calories from CHO: fat: protein) or control, fat restricted diet (55,20:25% daily calories from CHO: fat: protein). This family-based diet intervention included: (1) a 2-week supply of groceries to feed a four-person household specific to the assigned diet; and (2) extensive education on diet implementation through biweekly, diet-specific group and individualized counseling sessions with participants and one parent or guardian led by a registered dietitian (RD). The primary outcome measure of this study was hepatic lipid, measured using magnetic resonance spectroscopy (MRS). Secondary outcomes included liver transaminases; markers of inflammation (hsCRP, IL-6, TNF-α); body composition; visceral adipose tissue; and insulin resistance. All testing was conducted at baseline and week 8; hepatic transaminases were also measured at weeks 2 and 4. This RCT is registered with ClinicalTrials.gov (ID: NCT02787668).

Year of Publication
2018
Journal
Contemporary clinical trials
Volume
68
Number of Pages
95-101
Date Published
12/2018
ISSN Number
1559-2030
DOI
10.1016/j.cct.2018.03.014
Alternate Journal
Contemp Clin Trials
PMID
29601997
PMCID
PMC6411075
Download citation